GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (OTCPK:ONCWF) » Definitions » Current Deferred Revenue

ONCWF (Oncolytics Biotech) Current Deferred Revenue : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Oncolytics Biotech Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Oncolytics Biotech's current deferred revenue for the quarter that ended in Mar. 2025 was $0.00 Mil.

Oncolytics Biotech Current Deferred Revenue Historical Data

The historical data trend for Oncolytics Biotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Current Deferred Revenue Chart

Oncolytics Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncolytics Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oncolytics Biotech Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (OTCPK:ONCWF) » Definitions » Current Deferred Revenue
Comparable Companies
TSXV:COV XCNQ:ONCO TSXV:MIR TSX:SVA XCNQ:GLAB TSXV:NRX TSXV:SHRX TSX:MBX TSX:MDNA XCNQ:DTC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ONCY:USA ONC:Canada
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Website
https://www.oncolyticsbiotech.com
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.